IDT Opens Molecular Biology R&D Facility in Redwood City
Integrated DNA Technologies (IDT) is capitalizing on its expertise to deliver a broader range of validated molecular biology products. R&D for these products will now be performed in a newly built facility in Redwood City, California. The 8000-sq ft building houses labs that will allow IDT scientists to maximize the company’s custom oligonucleotide manufacturing capability.
This new Center of Excellence for R&D keeps IDT on the cutting edge of innovation in molecular biology applications, particularly qPCR, next generation sequencing (NGS), and synthetic biology (SynBio). “For years we’ve focused on enabling research,” said Stephen Gunstream, Chief Commercial Officer. “Redwood City takes that mission to the next level. Now, in addition to our traditional offerings, we will be able to develop complete workflow solutions for cutting edge applications. This provides more value to our customers.”
To lead Redwood City’s Product Development Team, IDT is pleased to announce that Dr Caifu Chen has joined the company as Senior Vice President for R&D. Dr Chen has 25 years of genomics research experience in the academic and biotech sectors, particularly in developing qPCR- and NGS-based assay products for research and diagnostics applications.
“I’m very excited to join the Redwood City team,” said Dr Chen. “We built this new facility for two reasons: One, to have a presence in the Bay Area, which is the worldwide center of the biotech industry. Second, we want to attract top talent that will develop innovative, robust solutions for NGS and qPCR. Robust products equal happier customers. This is our goal.”
“The addition of Dr Chen to our R&D team ensures that our customers can continue to rely on IDT to deliver impactful, high quality products in a timely manner,” said Dr Joseph A. Walder, founder and CEO of IDT. “Dr Chen will build and manage our team of R&D experts who will develop breakthrough genomic solutions.”
Related News
-
News Understanding the Benefits and Advances of Cleanroom Technology
In an industry where precision and sterility are crucial concerns, cleanrooms play a vital role in maintaining the integrity of pharmaceutical products like drugs, vaccines, and other medical products. So, what is a cleanroom?
-
News AbbVie secures GBP£1.2 billion deal for Gilgamesh’s psychedelic programme
AbbVie has penned a significant agreement to acquire the bretisilocin programme from Gilgamesh Pharmaceuticals for up to £1.2 billion, marking a bold step in the pharmaceutical giant's quest to develop treatments for psychiatric disorders. -
News Gates Foundation commits US$2.5 billion to women’s health research
The Bill & Melinda Gates Foundation has announced a substantial US$2.5 billion commitment to accelerate research and development focused exclusively on women's health through 2030.
-
News Mid-year review: notable FDA drug approvals of 2025
As we fly past the halfway point of 2025, the pharmaceutical landscape reliably continues to evolve with innovative therapies addressing critical medical needs. The FDA has already approved 17 groundbreaking medications this year, each representin... -
News US FDA announces new priority vouchers for accelerated review times
The US FDA announced a new priority program for drug developers – the Commissioner’s National Priority Voucher (CNPV) program aims to enhance the health interests of the US by allowing drug developers to redeem a voucher, shortening th... -
News Google-backed start-up raises US$600 million to support AI drug discovery and design
London-based Isomorphic Labs, an AI-driven drug design and development start-up backed by Google’s AI research lab DeepMind, has raised US$600 million in its first external funding round by Thrive Capital. The funding will provide further power t... -
News AstraZeneca to invest US$2.5 billion in Beijing R&D centre
Amid investigations of former AstraZeneca China head Leon Wang in 2024, AstraZeneca have outlined plans to establish its sixth global strategic R&D centre in China. Their aim is to further advance life sciences in China with major research and manufact... -
News Experimental drug for managing aortic valve stenosis shows promise
The new small molecule drug ataciguat is garnering attention for its potential to manage aortic valve stenosis, which may prevent the need for surgery and significantly improve patient experience.